Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 413

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial

Open access
Matas, Jose, Orrego, Mario, Amenabar, Diego, Infante, Catalina, Tapia-Limonchi, Rafael, Cadiz, Maria Ignacia, Alcayaga-Miranda, Francisca, González, Paz L., Muse, Emilio, Khoury, Maroun, Figueroa, Fernando E., Espinoza, Francisco·2019·Stem Cells Translational Medicine
DOI 10.1002/sctm.18-0053
Open this paper in CoChat — free account

Abstract

Knee osteoarthritis (OA) is a leading cause of pain and disability. Although conventional treatments show modest benefits, pilot and phase I/II trials with bone marrow (BM) and adipose-derived (AD) mesenchymal stromal cells (MSCs) point to the feasibility, safety, and occurrence of clinical and structural improvement in focal or diffuse disease. This study aimed to assess the safety and efficacy of the intra-articular injection of single or repeated umbilical cord-derived (UC) MSCs in knee OA. UC-MSCs were cultured in an International Organization for Standardization 9001:2015 certified Good Manufacturing Practice-type Laboratory. Patients with symptomatic knee OA were randomized to receive hyaluronic acid at baseline and 6 months (HA, n = 8), single-dose (20 × 106) UC-MSC at baseline (MSC-1, n = 9), or repeated UC-MSC doses at baseline and 6 months (20 × 106 × 2; MSC-2, n = 9). Clinical scores and magnetic resonance images (MRIs) were assessed throughout the 12 months follow-up. No severe adverse events were reported. Only MSC-treated patients experienced significant pain and function improvements from baseline (p = .001). At 12 months, Western Ontario and Mc Master Universities Arthritis Index (WOMAC-A; pain subscale) reached significantly lower levels of pain in the MSC-2-treated group (1.1 ± 1.3) as compared with the HA group (4.3 ± 3.5; p = .04). Pain Visual Analog scale was significantly lower in the MSC-2 group versus the HA group (2.4 ± 2.1 vs. 22.1 ± 9.8, p = .03) at 12 months. For total WOMAC, MSC-2 had lower scores than HA at 12 months (4.2 ± 3.9 vs. 15.2 ± 11, p = .05). No differences in MRI scores were detected. In a phase I/II trial (NCT02580695), repeated UC-MSC treatment is safe and superior to active comparator in knee OA at 1-year follow-up. Stem Cells Translational Medicine 2019;8:215&224

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/sctm.18-0053

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 51

  1. Abbott, 2017, The quality-of-life burden of knee osteoarthritis in New Zealand adults: A model-based evaluation, PLoS One, 12, e0185676, 10.1371/journal.pone.0185676 · DOI
  2. Losina, 2011, Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans, Ann Intern Med, 154, 217, 10.7326/0003-4819-154-4-201102150-00001 · DOI
  3. Liu, 2015, Knee osteoarthritis and all-cause mortality: The Wuchuan Osteoarthritis Study, Osteoarthr Cartil, 23, 1154, 10.1016/j.joca.2015.03.021 · DOI
  4. Gore, 2011, Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: A retrospective claims database analysis, J Med Econ, 14, 497, 10.3111/13696998.2011.594347 · DOI
  5. McKenna, 2005, Assessing the burden of disease in the United States using disability-adjusted life years, Am J Prev Med, 28, 415, 10.1016/j.amepre.2005.02.009 · DOI · Paper page
  6. Minas, 1997, Current concepts in the treatment of articular cartilage defects, Orthopedics, 20, 525, 10.3928/0147-7447-19970601-08 · DOI · Paper page
  7. Ogura, 2017, A 20-year follow-up after first-generation autologous chondrocyte implantation, Am J Sports Med, 45, 2751, 10.1177/0363546517716631 · DOI
  8. Barry, 2013, Mesenchymal stem cells in joint disease and repair, Nat Rev Rheumatol, 9, 584, 10.1038/nrrheum.2013.109 · DOI · Paper page
  9. Le Blanc, 2006, Mesenchymal stromal cells: Tissue repair and immune modulation, Cytotherapy, 8, 559, 10.1080/14653240601045399 · DOI
  10. François, 2006, Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: A study of their quantitative distribution after irradiation damage, Stem Cells, 24, 1020, 10.1634/stemcells.2005-0260 · DOI · Paper page
  11. Diekman, 2013, Intra-articular delivery of purified mesenchymal stem cells from C57BL/6 or MRL/MpJ superhealer mice prevents posttraumatic arthritis, Cell Transplant, 22, 1395, 10.3727/096368912X653264 · DOI
  12. Horie, 2012, Intra-articular injection of human mesenchymal stem cells (MSCs) promote rat meniscal regeneration by being activated to express Indian hedgehog that enhances expression of type II collagen, Osteoarthritis Cartilage, 20, 1197, 10.1016/j.joca.2012.06.002 · DOI
  13. Toghraie, 2012, Scaffold-free adipose-derived stem cells (ASCs) improve experimentally induced osteoarthritis in rabbits, Arch Iran Med, 15, 495
  14. Murphy, 2003, Stem cell therapy in a caprine model of osteoarthritis, Arthritis Rheum, 48, 3464, 10.1002/art.11365 · DOI · Paper page
  15. Huurne, 2012, Antiinflammatory and chondroprotective effects of intraarticular injection of adipose-derived stem cells in experimental osteoarthritis, Arthritis Rheum, 64, 3604, 10.1002/art.34626 · DOI · Paper page
  16. Saw, 2011, Articular cartilage regeneration with autologous peripheral blood progenitor cells and hyaluronic acid after arthroscopic subchondral drilling: A report of 5 cases with histology, Arthroscopy, 27, 493, 10.1016/j.arthro.2010.11.054 · DOI
  17. Saw, 2013, Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: A randomized controlled trial, Arthroscopy, 29, 684, 10.1016/j.arthro.2012.12.008 · DOI · Paper page
  18. Vangsness, 2014, Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: A randomized, double-blind, controlled study, J Bone Joint Surg Am, 96, 90, 10.2106/JBJS.M.00058 · DOI · Paper page
  19. Orozco, 2014, Treatment of knee osteoarthritis with autologous mesenchymal stem cells: Two-year follow-up results, Transplantation, 97, e66, 10.1097/TP.0000000000000167 · DOI
  20. Jo, 2014, Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: A proof-of-concept clinical trial, Stem Cells, 32, 1254, 10.1002/stem.1634 · DOI · Paper page
  21. Pers, 2016, Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: A phase I dose-escalation trial, Stem Cells Translational Medicine, 5, 847, 10.5966/sctm.2015-0245 · DOI · Paper page
  22. Vega, 2015, Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: A randomized controlled trial, Transplantation, 99, 1681, 10.1097/TP.0000000000000678 · DOI · Paper page
  23. Bartolucci, 2017, Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: A phase 1/2 randomized controlled trial (RIMECARD trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]), Circ Res, 121, 1192, 10.1161/CIRCRESAHA.117.310712 · DOI · Paper page
  24. González, 2015, Chorion mesenchymal stem cells show superior differentiation, immunosuppressive, and angiogenic potentials in comparison with haploidentical maternal placental cells, Stem Cells Translational Medicine, 4, 1109, 10.5966/sctm.2015-0022 · DOI
  25. Park, 2017, Cartilage regeneration in osteoarthritic patients by a composite of allogeneic umbilical cord blood-derived mesenchymal stem cells and hyaluronate hydrogel: Results from a clinical trial for safety and proof-of-concept with 7 years of extended follow-up, Stem Cells Translational Medicine, 6, 613, 10.5966/sctm.2016-0157 · DOI · Paper page
  26. Lohan, 2017, Anti-donor immune responses elicited by allogeneic mesenchymal stem cells and their extracellular vesicles: Are we still learning?, Front Immunol, 8, 1626, 10.3389/fimmu.2017.01626 · DOI
  27. Escobar, 2002, Validation of the Spanish version of the WOMAC questionnaire for patients with hip or knee osteoarthritis, Clin Rheumatol, 21, 466, 10.1007/s100670200117 · DOI · Paper page
  28. Alonso, 1998, The Spanish version of the SF-36 health survey (the SF-36 health questionnaire): An instrument for measuring clinical results [in Spanish], Med Clin (Barc), 104, 771
  29. Dougados, 2000, Response criteria for clinical trials on osteoarthritis of the knee and hip: A report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative, Osteoarthritis Cart, 8, 395, 10.1053/joca.2000.0361 · DOI
  30. Peterfy, 2004, Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis, Osteoarthritis Cartilage, 12, 177, 10.1016/j.joca.2003.11.003 · DOI · Paper page
  31. Jeong, 2013, Thrombospondin-2 secreted by human umbilical cord blood-derived mesenchymal stem cells promotes chondrogenic differentiation, Stem Cells, 31, 2136, 10.1002/stem.1471 · DOI
  32. Kyurkchiev, 2014, Secretion of immunoregulatory cytokines by mesenchymal stem cells, World J Stem Cells, 6, 552, 10.4252/wjsc.v6.i5.552 · DOI · Paper page
  33. Zhang, 2017, Regeneration of hyaline-like cartilage in situ with SOX9 stimulation of bone marrow-derived mesenchymal stem cells, PLoS One, 12, e0180138, 10.1371/journal.pone.0180138 · DOI
  34. Ichiseki, 2018, Intraarticularly-injected mesenchymal stem cells stimulate anti-inflammatory molecules and inhibit pain related protein and chondrolytic enzymes in a monoiodoacetate-induced rat arthritis model, Int J Mol Sci, 19, E203, 10.3390/ijms19010203 · DOI
  35. Saulnier, 2015, Intra-articular administration of xenogeneic neonatal mesenchymal stromal cells early after meniscal injury down-regulates metalloproteinase gene expression in synovium and prevents cartilage degradation in a rabbit model of osteoarthritis, Osteoarthritis Cartilage, 23, 122, 10.1016/j.joca.2014.09.007 · DOI
  36. Xing, 2016, Intra-articular hyaluronic acid in treating knee-osteoarthritis: A PRISMA-compliant systemic review of overlapping metanalysis, Sci Rep, 6, 32790, 10.1038/srep32790 · DOI
  37. Bellamy, 2006, Viscosupplementation for the treatment of osteoarthritis of the knee, Cochrane Database Syst Rev, 2, CD005321
  38. Zhang, 2008, The placebo effect and its determinants in osteoarthritis: Meta-analysis of randomized controlled trials, Ann Rheum Dis, 67, 1716, 10.1136/ard.2008.092015 · DOI · Paper page
  39. Rutjes, 2012, Viscosupplementation for osteoarthritis of the knee: A systematic review and meta-analysis, Ann Intern Med, 157, 180, 10.7326/0003-4819-157-3-201208070-00473 · DOI · Paper page
  40. Leighton, 2014, NASHA hyaluronic acid vs. methylprednisolone for knee osteoarthritis: A prospective, multi-centre, randomized, non-inferiority trial, Osteoarthritis Cartilage, 22, 17, 10.1016/j.joca.2013.10.009 · DOI
  41. Mandl, 2015, Relative efficacy of knee osteoarthritis treatments: Are all placebos created equal?, Ann Intern Med, 162, 71, 10.7326/M14-2636 · DOI
  42. Strand, 2012, A multicenter, randomized controlled trial comparing a single intra-articular injection of Gel-200, a new cross-linked formulation of hyaluronic acid, to phosphate buffered saline for treatment of osteoarthritis of the knee, Osteoarthritis Cartilage, 20, 350, 10.1016/j.joca.2012.01.013 · DOI
  43. Soler, 2016, Final results of a phase I-II trial using ex vivo expanded autologous mesenchymal stromal cells for the treatment of osteoarthritis of the knee confirming safety and suggesting cartilage regeneration, Knee, 23, 647, 10.1016/j.knee.2015.08.013 · DOI
  44. Lamo-Espinosa, 2016, Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: Multicenter randomized controlled clinical trial (phase I/II), J Transl Med, 14, 246, 10.1186/s12967-016-0998-2 · DOI · Paper page
  45. Caplan, 2009, Why are MSCs therapeutic? New data: New insight, J Pathol, 217, 318, 10.1002/path.2469 · DOI · Paper page
  46. Murphy, 2002, Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis, Arthritis Rheum, 46, 704, 10.1002/art.10118 · DOI · Paper page
  47. Kim, 2010, Application of human umbilical cord blood-derived mesenchymal stem cells in disease models, World J Stem Cells, 2, 34, 10.4252/wjsc.v2.i2.34 · DOI
  48. Gupta, 2016, Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel®): Preclinical and clinical trial in osteoarthritis of the knee joint, Arthritis Res Ther, 18, 301, 10.1186/s13075-016-1195-7 · DOI · Paper page
  49. Ozeki, 2016, Not single but periodic injections of synovial mesenchymal stem cells maintain viable cells in knees and inhibit osteoarthritis progression in rats, Osteoarthritis Cartil, 24, 1061, 10.1016/j.joca.2015.12.018 · DOI
  50. Joswig, 2017, Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model, Stem Cell Res Ther, 8, 42, 10.1186/s13287-017-0503-8 · DOI
  51. Panés, 2016, Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: A phase 3 randomised, double-blind controlled trial, Lancet, 388, 1281, 10.1016/S0140-6736(16)31203-X · DOI · Paper page

Cited by

Metadata

Authors
Matas, J., Orrego, M., Amenabar, D., Infante, C., Tapia-Limonchi, R., Cadiz, M. I., Alcayaga-Miranda, F., González, P. L., Muse, E., Khoury, M., Figueroa, F. E., & Espinoza, F.
Venue
Stem Cells Translational Medicine
Publisher
Oxford University Press (OUP)
Published
2018-12-28
Volume
8
Issue
3
Pages
215-224
ISSN
  • 2157-6564 (ISSN-L)
  • 2157-6580
DOI
10.1002/sctm.18-0053
OpenAlex
W2907679499
Cited by
413
References
2
FWCI
21.10
Type
journal article
Language
en
Open access
gold
Licence
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 1041 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.